- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CITIUS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Fr | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Citius Oncology closes $9 million public offering to support LYMPHIR | 3 | Investing.com | ||
| Mi | Citius Oncology announces pricing of $9 million public offering | 1 | Seeking Alpha | ||
| Di | Citius Oncology stock rises after expanding LYMPHIR distribution network | 3 | Investing.com | ||
| 14.07. | CITIUS ONCOLOGY, INC. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 14.07. | Citius Oncology launches $15M equity and warrant offering; shares down | 1 | Seeking Alpha | ||
| 14.07. | CITIUS ONCOLOGY, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 27.06. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 17.06. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Citius Oncology prepares for lymphoma treatment launch in 2025 | 3 | Investing.com | ||
| 09.06. | Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR | 375 | AFX News | WASHINGTON (dpa-AFX) - Citius Oncology, Inc. (CTOR), the oncology-focused subsidiary of late-stage biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR), announced Monday it has entered... ► Artikel lesen | |
| 09.06. | Citius Oncology stock soars on distribution deal | 4 | Investing.com | ||
| 09.06. | Citius Oncology enters distribution services agreement with Cardinal Health | 7 | Seeking Alpha | ||
| 09.06. | Citius Oncology-Aktie steigt nach Vertriebsvereinbarung stark an | 4 | Investing.com Deutsch | ||
| 09.06. | Citius Oncology partners with Cardinal Health for LYMPHIR distribution | 4 | Investing.com | ||
| 09.06. | Citius Oncology kooperiert mit Cardinal Health für LYMPHIR-Vertrieb | 3 | Investing.com Deutsch | ||
| 14.05. | CITIUS ONCOLOGY, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update | 137 | PR Newswire | CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company... ► Artikel lesen | |
| 03.04. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 35,050 | -0,57 % | Zwischen Aufbruch und Wandel: Biotech im Check: Wo liegen die Chancen? - BB Biotech: Diversifizierung innerhalb einer Aktie | Steht die Biotech-Branche vor einem strukturellen Wandel? Enormes Innovationspotenzial und gute Voraussetzungen für M&A-Aktivitäten könnten Schwung in den Sektor bringen. Wie geht es eigentlich der... ► Artikel lesen | |
| QIAGEN | 41,300 | -0,25 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| NOVAVAX | 6,040 | +0,20 % | UNGLAUBLICHE Sondermeldung bei Novavax Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| STRYKER | 332,90 | -0,63 % | Kurs von Stryker fällt ab (334,4293 €) | Im US-amerikanischen Wertpapierhandel liegt die Aktie von Stryker gegenwärtig im Minus. Der jüngste Kurs betrug 387,52 US-Dollar. Die Aktie von Stryker verzeichnet aktuell einen Kursrückgang von 0,86... ► Artikel lesen | |
| ILLUMINA | 80,01 | -3,29 % | Illumina Stock: What Went Wrong And Why It's Best To Stay Away | ||
| CRISPR THERAPEUTICS | 57,50 | +2,68 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| AAP IMPLANTATE | 2,000 | +2,04 % | EQS-News: aap Implantate AG schließt das Geschäftsjahr 2024 erfolgreich ab - positive Entwicklungen trotz herausforderndem Umfeld | EQS-News: aap Implantate AG
/ Schlagwort(e): Jahresbericht
aap Implantate AG schließt das Geschäftsjahr 2024 erfolgreich ab - positive Entwicklungen trotz herausforderndem Umfeld... ► Artikel lesen | |
| OCUGEN | 0,903 | +3,37 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,446 | +3,03 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,425 | +0,43 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,373 | +0,08 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,393 | -3,68 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,516 | +1,38 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Second Quarter 2025 Financial Results on August 4 | ||
| TEMPUS AI | 53,00 | +0,95 % | Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer |
Das Unternehmen CITIUS ONCOLOGY INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,570 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CITIUS ONCOLOGY INC finden Sie auf Wallstreet Online.